Literature DB >> 19026940

Medications for weight reduction.

George A Bray1.   

Abstract

Only two drugs are currently approved for long-term use in the treatment of obesity and four others for short-term use. Evaluating the risk-benefit profile is an essential first step. For individuals who have a low body mass index for whom the risk is small, the risk profile must make the drug acceptable for almost everyone. For higher-risk patients, such as those planning intestinal bypass or who have sleep apnea, a wider range of drugs may be considered. Obesity is a chronic disease that has many causes. Treatment is aimed at palliation-that is, producing and maintaining weight loss. Regardless of the primary site of action, the net effect must be a reduction in food intake or increase in energy expenditure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19026940     DOI: 10.1016/j.ecl.2008.08.004

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  8 in total

1.  Heritability of the weight loss response to gastric bypass surgery.

Authors:  Ida J Hatoum; Danielle M Greenawalt; Chris Cotsapas; Marc L Reitman; Mark J Daly; Lee M Kaplan
Journal:  J Clin Endocrinol Metab       Date:  2011-08-10       Impact factor: 5.958

2.  Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgery.

Authors:  Ida J Hatoum; Nicholas Stylopoulos; Amanda M Vanhoose; Kelli L Boyd; Deng Ping Yin; Kate L J Ellacott; Lian Li Ma; Kasia Blaszczyk; Julia M Keogh; Roger D Cone; I Sadaf Farooqi; Lee M Kaplan
Journal:  J Clin Endocrinol Metab       Date:  2012-04-06       Impact factor: 5.958

Review 3.  What are the risks and the benefits of current and emerging weight-loss medications?

Authors:  Jamie R Robinson; Kevin D Niswender
Journal:  Curr Diab Rep       Date:  2009-10       Impact factor: 4.810

4.  Weight loss after gastric bypass is associated with a variant at 15q26.1.

Authors:  Ida J Hatoum; Danielle M Greenawalt; Chris Cotsapas; Mark J Daly; Marc L Reitman; Lee M Kaplan
Journal:  Am J Hum Genet       Date:  2013-05-02       Impact factor: 11.025

5.  Advantages of percent weight loss as a method of reporting weight loss after Roux-en-Y gastric bypass.

Authors:  Ida J Hatoum; Lee M Kaplan
Journal:  Obesity (Silver Spring)       Date:  2013-05-13       Impact factor: 5.002

6.  Quantifying energy intake changes during obesity pharmacotherapy.

Authors:  Britta Göbel; Arjun Sanghvi; Kevin D Hall
Journal:  Obesity (Silver Spring)       Date:  2014-06-24       Impact factor: 5.002

7.  Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass.

Authors:  Pernille Barkholt; Philip J Pedersen; Anders Hay-Schmidt; Jacob Jelsing; Henrik H Hansen; Niels Vrang
Journal:  Mol Metab       Date:  2016-01-25       Impact factor: 7.422

8.  Proportional Feedback Control of Energy Intake During Obesity Pharmacotherapy.

Authors:  Kevin D Hall; Arjun Sanghvi; Britta Göbel
Journal:  Obesity (Silver Spring)       Date:  2017-10-25       Impact factor: 5.002

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.